# a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

> **NCT07007949** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 42 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- IDH1 Gene Mutation
- Ivosidenib

## Interventions

- **DRUG:** Ivosidenib combined with venetoclax and azacitidine
- **DRUG:** Ivosidenib combined with venetoclax and azacitidine

## Key facts

- **NCT ID:** NCT07007949
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07007949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07007949, "a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07007949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*